SILO PHARMA, INC. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
SILO PHARMA, INC. (SILO) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of -$3.91 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2023-03-24
- SILO PHARMA, INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2022 was -$3.91M, a 241.93% decline from fiscal 2021.
- SILO PHARMA, INC. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2021 was $2.75M.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|
| 2022-12-31 | -$3.91M 10-K · filed 2023-03-24 |
| 2021-12-31 | $2.75M 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |